William J Mackillop1, Weidong Kong2, Michael Brundage2, Timothy P Hanna2, Jina Zhang-Salomons2, Pierre-Yves McLaughlin2, Scott Tyldesley3. 1. Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada. Electronic address: william.mackillop@krcc.on.ca. 2. Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada. 3. Vancouver Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Abstract
PURPOSE: Estimates of the appropriate rate of use of radiation therapy (RT) are required for planning and monitoring access to RT. Our objective was to compare estimates of the appropriate rate of use of RT derived from mathematical models, with the rate observed in a population of patients with optimal access to RT. METHODS AND MATERIALS: The rate of use of RT within 1 year of diagnosis (RT1Y) was measured in the 134,541 cases diagnosed in Ontario between November 2009 and October 2011. The lifetime rate of use of RT (RTLIFETIME) was estimated by the multicohort utilization table method. Poisson regression was used to evaluate potential barriers to access to RT and to identify a benchmark subpopulation with unimpeded access to RT. Rates of use of RT were measured in the benchmark subpopulation and compared with published evidence-based estimates of the appropriate rates. RESULTS: The benchmark rate for RT1Y, observed under conditions of optimal access, was 33.6% (95% confidence interval [CI], 33.0%-34.1%), and the benchmark for RTLIFETIME was 41.5% (95% CI, 41.2%-42.0%). Benchmarks for RTLIFETIME for 4 of 5 selected sites and for all cancers combined were significantly lower than the corresponding evidence-based estimates. Australian and Canadian evidence-based estimates of RTLIFETIME for 5 selected sites differed widely. RTLIFETIME in the overall population of Ontario was just 7.9% short of the benchmark but 20.9% short of the Australian evidence-based estimate of the appropriate rate. CONCLUSIONS: Evidence-based estimates of the appropriate lifetime rate of use of RT may overestimate the need for RT in Ontario.
PURPOSE: Estimates of the appropriate rate of use of radiation therapy (RT) are required for planning and monitoring access to RT. Our objective was to compare estimates of the appropriate rate of use of RT derived from mathematical models, with the rate observed in a population of patients with optimal access to RT. METHODS AND MATERIALS: The rate of use of RT within 1 year of diagnosis (RT1Y) was measured in the 134,541 cases diagnosed in Ontario between November 2009 and October 2011. The lifetime rate of use of RT (RTLIFETIME) was estimated by the multicohort utilization table method. Poisson regression was used to evaluate potential barriers to access to RT and to identify a benchmark subpopulation with unimpeded access to RT. Rates of use of RT were measured in the benchmark subpopulation and compared with published evidence-based estimates of the appropriate rates. RESULTS: The benchmark rate for RT1Y, observed under conditions of optimal access, was 33.6% (95% confidence interval [CI], 33.0%-34.1%), and the benchmark for RTLIFETIME was 41.5% (95% CI, 41.2%-42.0%). Benchmarks for RTLIFETIME for 4 of 5 selected sites and for all cancers combined were significantly lower than the corresponding evidence-based estimates. Australian and Canadian evidence-based estimates of RTLIFETIME for 5 selected sites differed widely. RTLIFETIME in the overall population of Ontario was just 7.9% short of the benchmark but 20.9% short of the Australian evidence-based estimate of the appropriate rate. CONCLUSIONS: Evidence-based estimates of the appropriate lifetime rate of use of RT may overestimate the need for RT in Ontario.
Authors: Chun Chieh Lin; Suanna S Bruinooge; M Kelsey Kirkwood; Dawn L Hershman; Ahmedin Jemal; B Ashleigh Guadagnolo; James B Yu; Shane Hopkins; Michael Goldstein; Dean Bajorin; Sharon H Giordano; Michael Kosty; Anna Arnone; Amy Hanley; Stephanie Stevens; Christine Olsen Journal: Int J Radiat Oncol Biol Phys Date: 2015-12-17 Impact factor: 7.038
Authors: Wei Liu; Alissa Liu; Jessica Chan; R Gabriel Boldt; Pablo Munoz-Schuffenegger; Alexander V Louie Journal: Transl Lung Cancer Res Date: 2019-09
Authors: Safiya Karim; William J Mackillop; Kelly Brennan; Yingwei Peng; D Robert Siemens; Monika K Krzyzanowska; Christopher M Booth Journal: Cancer Med Date: 2019-08-31 Impact factor: 4.452
Authors: Safiya Karim; Christopher M Booth; Kelly Brennan; Yingwei Peng; D Robert Siemens; Monika K Krzyzanowska; William J Mackillop Journal: Cancer Med Date: 2019-08-12 Impact factor: 4.452
Authors: J L Hamilton; S Foxcroft; E Moyo; J Cooke-Lauder; T Spence; P Zahedi; A Bezjak; D Jaffray; C Lam; D Létourneau; M Milosevic; R Tsang; R Wong; F F Liu Journal: Curr Oncol Date: 2017-12-20 Impact factor: 3.677